Long-term tolerability of a new epoprostenol formulation in patients with pulmonary arterial hypertension

Trial Profile

Long-term tolerability of a new epoprostenol formulation in patients with pulmonary arterial hypertension

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2014

At a glance

  • Drugs Epoprostenol (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms EPITOME-2
  • Most Recent Events

    • 30 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top